Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from AIM ImmunoTech ( (AIM) ) is now available.
On December 16, 2025, AIM ImmunoTech held its 2025 Annual Meeting of Stockholders, during which essential governance matters were voted on. Key outcomes included the election of directors, approval of the company’s independent accounting firm, shareholder approval for executive compensation on an advisory basis despite not meeting required majority voting power, and the decision to hold annual advisory votes on executive compensation.
The most recent analyst rating on (AIM) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
AIM ImmunoTech’s overall stock score is heavily impacted by its poor financial performance and valuation. The company’s significant financial challenges, including persistent losses and a weak balance sheet, are the most critical factors. Technical analysis also points to a bearish trend, further weighing down the score. The absence of positive earnings call data or corporate events leaves little room for optimism.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech Inc. operates within the biotechnology industry, focusing on the development of therapeutic solutions for immune system modulation and virus-related diseases.
Average Trading Volume: 107,118
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.06M
See more data about AIM stock on TipRanks’ Stock Analysis page.